According to the interim trial results, Russia’s Sputnik V vaccine is 92% effective at protecting people from COVID-19.
Russia’s results are only the second from a late-stage human trial, following on swiftly from data released on Monday by Pfizer Inc and BioNTech, which said their shot was also more than 90% effective.
According to the report, while experts said the Russian data was encouraging and reinforced the idea the pandemic could be halted by vaccines, they warned that the results were only based on a small number of trial volunteers who had contracted COVID-19.
The analysis was conducted after 20 participants developed the virus and examined how many had received the vaccine versus a placebo. That is significantly lower than the 94 infections in the trial of the vaccine being developed by Pfizer and BioNTech.
Bodo Plachter, deputy director of the Institute of Virology at the Mainz University said, “I assume there was political pressure after the press release from Pfizer and BioNTech earlier in the week to now draw level with their own data. What is missing for now is an analysis of statistical significance.”
To confirm the effectiveness rate of its vaccine, Pfizer said it would continue its trial until there were 164 COVID-19 cases.